How can investment in the life sciences sector be improved?

14 November 2017

The House of Lords Science and Technology Committee continues taking evidence for its inquiry into Life Sciences and the Industrial Strategy. The Committee hears evidence from life science investors; plant and animal scientists and science parks.

Purpose of sessions

Over three evidence sessions the Committee explore the barriers that prevent the UK life sciences receiving investment; how infrastructure can support the development of life science clusters in the UK; and which areas of the strategy may need greater emphasis due to Brexit.

Witnesses

Tuesday 14 November in Committee Room 4A, Place of Westminster

At 10.10am

Professor Angela Karp, Director for Science Innovation, Engagement and Partnerships, Rothamsted Research
Dr Dave Hughes, Head of Global R&D Technology Scouting, Syngenta
Professor Jonathan Elliott, Vice-Principal, Research and Innovation, Royal Veterinary College

At 11.00am

Dr Mark Hammond, Co-founder, Deep Science Ventures;
John Bowler, Fund Manager and Global Sector Specialist with responsibility for the health care sector, Schroders PLC
Dr Peter Hughes, Healthcare Equity Analyst, AXA Framlington Biotech Fund
Dr Andrew Elder, Partner, Albion Capital

At 11.50am

Dr Glenn Crocker MBE, Representative of the UK Science Parks Association and Chief Executive of BioCity Nottingham
Dr Iain Thomas, Head of Life Sciences, Cambridge Enterprise
Dr Sally Ann Forsyth, Chief Executive Officer, Norwich Research Park

Possible questions

What further action is needed to engage the investor community?
Who should be responsible for implementing the life sciences strategy, and what role should the investor community play?
How important is the right infrastructure to the success of a cluster or science park and how should this infrastructure be financed?
Should the scope of the strategy be broadened to include life sciences outside of the bio-medical sciences?

Further information

Image: iStockphoto